2196:HKEXEscrit Inc. Analysis
Data as of 2026-08-31 - not real-time
HK$15.99
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is priced at HKD 15.99, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has lost 4.0%. RSI sits at 41.8, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at HKD 15.80 up to resistance at HKD 18.49.
On valuation the read is undervalued — earnings multiple of 10.7 versus a 30.2 sector average, below the peer group. The average analyst target implies 71.1% above today's level. Revenue is growing at 2.7% on a 8.0% profit margin. The 2.73% dividend yield looks covered by current payout levels.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 36.5%, a beta of 0.20 and a maximum drawdown of 47.7%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
On valuation the read is undervalued — earnings multiple of 10.7 versus a 30.2 sector average, below the peer group. The average analyst target implies 71.1% above today's level. Revenue is growing at 2.7% on a 8.0% profit margin. The 2.73% dividend yield looks covered by current payout levels.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 36.5%, a beta of 0.20 and a maximum drawdown of 47.7%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
Top Market Events
Detailed price information for Shanghai Fosun Pharmaceutical Group CO Ltd SFOSF from The Globe and Mail including...Detailed price information for Shanghai Fosun Pharmaceutical Group CO Ltd SFOSF from The Globe and Mail including...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 19.00
- MACD momentum is negative
- Maximum drawdown of 47.7%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 10.7 versus sector average of 30.2
- Trading below the 200-day average of 19.00
- Analyst targets imply +71.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 10.7 versus sector average of 30.2
- Analyst targets imply +71.1% versus the current price
- Dividend yield of 2.73%
Key Metrics & Analysis
Financial Health
Revenue Growth2.70%
Profit Margin7.96%
P/E Ratio10.7
ROE6.95%
ROA1.40%
Debt/Equity61.69
P/B Ratio0.7
Op. Cash FlowHK$5.5B
Free Cash FlowHK$2.3B
Industry P/E30.2
Technical Analysis
TrendNeutral
RSI41.8
SupportHK$15.80
ResistanceHK$18.49
MA 20HK$16.84
MA 50HK$16.45
MA 200HK$19.00
MACDBearish
VolumeIncreasing
Fear & Greed Index94.11
Valuation
Fair ValueHK$3.57
Target PriceHK$27.36
Upside/Downside71.11%
GradeUndervalued
TypeValue
Dividend Yield2.73%
Risk Assessment
Beta0.20
Volatility36.51%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.